Compare Stocks: IONS, ALNY, BIIB, and ROIV

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$239.56 -2.4%	$247.29	$197.81 ▼ $495.55	$32.06B	0.31	1.56 million shs	2.76 million shs
BIIB Biogen	$215.50 -1.6%	$211.00	$135.39 ▼ $225.80	$31.84B	0.17	679,223 shs	2.63 million shs
IONS Ionis Pharmaceuticals	$44.44 -4.9%	$55.97	$44.27 ▼ $86.74	$7.39B	0.42	3.40 million shs	7.37 million shs
ROIV Roivant Sciences	$39.77 -0.5%	$36.18	$14.50 ▼ $42.50	$28.73B	1.12	8.86 million shs	32.20 million shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	0.00%	-3.67%	+4.47%	-13.86%	-46.97%
BIIB Biogen	0.00%	-0.76%	+0.54%	+9.62%	+48.75%
IONS Ionis Pharmaceuticals	0.00%	-18.02%	-24.37%	-40.04%	-27.35%
ROIV Roivant Sciences	0.00%	-2.57%	+7.95%	+26.54%	+160.27%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$239.56 -2.4%	$247.29	$197.81 ▼ $495.55	$32.06B	0.31	1.56 million shs	2.76 million shs
BIIB Biogen	$215.50 -1.6%	$211.00	$135.39 ▼ $225.80	$31.84B	0.17	679,223 shs	2.63 million shs
IONS Ionis Pharmaceuticals	$44.44 -4.9%	$55.97	$44.27 ▼ $86.74	$7.39B	0.42	3.40 million shs	7.37 million shs
ROIV Roivant Sciences	$39.77 -0.5%	$36.18	$14.50 ▼ $42.50	$28.73B	1.12	8.86 million shs	32.20 million shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	0.00%	-3.67%	+4.47%	-13.86%	-46.97%
BIIB Biogen	0.00%	-0.76%	+0.54%	+9.62%	+48.75%
IONS Ionis Pharmaceuticals	0.00%	-18.02%	-24.37%	-40.04%	-27.35%
ROIV Roivant Sciences	0.00%	-2.57%	+7.95%	+26.54%	+160.27%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNY Alnylam Pharmaceuticals	2.87	Moderate Buy	$367.20	53.28% Upside
BIIB Biogen	2.58	Moderate Buy	$230.14	6.79% Upside
IONS Ionis Pharmaceuticals	2.73	Moderate Buy	$90.80	104.32% Upside
ROIV Roivant Sciences	2.85	Moderate Buy	$45.64	14.75% Upside

Current Analyst Ratings Breakdown

Latest IONS, ALNY, BIIB, and ROIV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/16/2026	ROIV Roivant Sciences	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$51.00
9/15/2026	IONS Ionis Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$89.00 ➝ $80.00
9/10/2026	BIIB Biogen	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$242.00
9/10/2026	BIIB Biogen	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Reduce	$165.00 ➝ $175.00
9/9/2026	ROIV Roivant Sciences	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$42.00 ➝ $46.00
9/9/2026	ROIV Roivant Sciences	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$55.00
9/9/2026	ROIV Roivant Sciences	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$50.00 ➝ $55.00
9/9/2026	IONS Ionis Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$90.00 ➝ $85.00
9/8/2026	IONS Ionis Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$84.00
9/8/2026	IONS Ionis Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$110.00 ➝ $104.00
9/8/2026	IONS Ionis Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$3.71B	8.63	$2.80 per share	85.68	$5.97 per share	40.13
BIIB Biogen	$9.89B	3.22	$22.64 per share	9.52	$124.45 per share	1.73
IONS Ionis Pharmaceuticals	$944M	7.82	N/A	N/A	$3.02 per share	14.72
ROIV Roivant Sciences	$8.26M	3,477.80	N/A	N/A	$7.35 per share	5.41

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	$313.75M	$5.38	44.53	24.70	N/A	15.26%	84.93%	14.30%	10/29/2026 (Estimated)
BIIB Biogen	$1.29B	$5.65	38.14	13.38	2.38	8.32%	11.18%	6.88%	10/28/2026 (Estimated)
IONS Ionis Pharmaceuticals	-$381.39M	-$3.46	N/A	N/A	N/A	-64.76%	-111.08%	-17.41%	11/4/2026 (Estimated)
ROIV Roivant Sciences	-$299.77M	-$0.53	N/A	N/A	N/A	-3,534.96%	-22.94%	-21.53%	11/9/2026 (Estimated)

Latest IONS, ALNY, BIIB, and ROIV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2026	Q1 2027	ROIV Roivant Sciences	-$0.2996	-$0.26	+$0.0396	-$0.26	$2.06 million	$1.44 million
7/30/2026	Q2 2026	ALNY Alnylam Pharmaceuticals	$1.63	$1.84	+$0.21	$1.21	$1.32 billion	$1.29 billion
7/29/2026	Q2 2026	BIIB Biogen	$2.94	$3.60	+$0.66	$0.66	$2.46 billion	$2.74 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
IONS Ionis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ROIV Roivant Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	0.75	3.05	2.99
BIIB Biogen	0.39	1.87	1.26
IONS Ionis Pharmaceuticals	3.07	7.89	7.73
ROIV Roivant Sciences	N/A	16.72	16.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
BIIB Biogen	87.93%
IONS Ionis Pharmaceuticals	93.86%
ROIV Roivant Sciences	64.76%

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	0.86%
BIIB Biogen	0.25%
IONS Ionis Pharmaceuticals	1.81%
ROIV Roivant Sciences	8.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,770	133.81 million	132.66 million	Optionable
BIIB Biogen	7,500	147.75 million	147.39 million	Optionable
IONS Ionis Pharmaceuticals	1,402	166.18 million	163.18 million	Optionable
ROIV Roivant Sciences	721	722.32 million	658.76 million	Optionable

IONS, ALNY, BIIB, and ROIV Headlines

Recent News About These Companies

What Is Roivant Sciences (ROIV) Signaling With Its Positive PH ILD Trial Data?

September 18 at 8:21 AM | finance.yahoo.com

Roivant Shareholders Approve Directors and Governance Matters

September 18 at 7:51 AM | tipranks.com

Roivant Sciences (NASDAQ:ROIV) Director Sells 4,938 Shares

September 18 at 7:22 AM | insidertrades.com

Stifel initiates coverage of Roivant Sciences with buy rating

September 17 at 10:19 PM | msn.com

Insider Selling: Roivant Sciences (NASDAQ:ROIV) Director Sells 4,938 Shares of Stock

September 17 at 7:07 PM | marketbeat.com

Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Average Recommendation of "Moderate Buy" from Analysts

September 17 at 3:14 AM | americanbankingnews.com

California State Teachers Retirement System Raises Holdings in Roivant Sciences Ltd. $ROIV

September 14, 2026 | marketbeat.com

Roivant Sciences: Diverse Exposure To Biotech Niches Through Vants

September 13, 2026 | seekingalpha.com

Roivant Sciences Ltd. (ROIV)’s Pulmonary Hypertension Breakthrough Could Transform Its Growth Story

September 13, 2026 | insidermonkey.com

Roivant Sciences Ltd. (NASDAQ:ROIV) Given Average Rating of "Moderate Buy" by Analysts

September 12, 2026 | marketbeat.com

Arizona State Retirement System Has $4.54 Million Position in Roivant Sciences Ltd. $ROIV

September 12, 2026 | marketbeat.com

Roivant Sciences (ROIV) Gets a Buy from TD Cowen

September 11, 2026 | theglobeandmail.com

Health News Round-Up: Latest Breakthroughs and Challenges

September 11, 2026 | devdiscourse.comD

61,200 Shares in Roivant Sciences Ltd. $ROIV Bought by VIRGINIA RETIREMENT SYSTEMS ET Al

September 11, 2026 | marketbeat.com

Roivant Sciences Ltd. (ROIV) Discusses Top Line Results from PHocus Study of Mosliciguat in PH-ILD - Slideshow

September 10, 2026 | seekingalpha.com

Roivant Sciences Ltd. (ROIV) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

September 10, 2026 | seekingalpha.com

Squarepoint Ops LLC Buys Shares of 475,571 Roivant Sciences Ltd. $ROIV

September 10, 2026 | marketbeat.com

Stock Traders Purchase Large Volume of Call Options on Roivant Sciences (NASDAQ:ROIV)

September 10, 2026 | americanbankingnews.com

Jefferies Financial Group Boosts Roivant Sciences (NASDAQ:ROIV) Price Target to $52.00

September 10, 2026 | americanbankingnews.com

HC Wainwright Raises Roivant Sciences (NASDAQ:ROIV) Price Target to $47.00

September 10, 2026 | americanbankingnews.com

Revolutionary Strides in Healthcare: From Lung Disease Breakthroughs to Fertility Support

September 9, 2026 | devdiscourse.comD

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IONS, ALNY, BIIB, and ROIV Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

$239.56 -5.95 (-2.42%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$239.62 +0.06 (+0.02%)

As of 09/18/2026 07:30 PM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Biogen NASDAQ:BIIB

$215.50 -3.55 (-1.62%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$217.00 +1.50 (+0.70%)

As of 09/18/2026 07:58 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Ionis Pharmaceuticals NASDAQ:IONS

$44.44 -2.31 (-4.94%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$44.59 +0.15 (+0.34%)

As of 09/18/2026 07:58 PM Eastern

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Roivant Sciences NASDAQ:ROIV

$39.77 -0.21 (-0.53%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$40.33 +0.56 (+1.40%)

As of 09/18/2026 07:30 PM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IONS, ALNY, BIIB, and ROIV Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IONS, ALNY, BIIB, and ROIV Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IONS, ALNY, BIIB, and ROIV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IONS, ALNY, BIIB, and ROIV Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Biogen NASDAQ:BIIB

Ionis Pharmaceuticals NASDAQ:IONS

Roivant Sciences NASDAQ:ROIV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IONS, ALNY, BIIB, and ROIV Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IONS, ALNY, BIIB, and ROIV Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IONS, ALNY, BIIB, and ROIV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IONS, ALNY, BIIB, and ROIV Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Biogen NASDAQ:BIIB

Ionis Pharmaceuticals NASDAQ:IONS

Roivant Sciences NASDAQ:ROIV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools